Loading, Please Wait...
Salt Lake City, Utah, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be presenting at the 71st annual AACC Scientific Meeting and Clinical Lab Expo in Anaheim, California on August 4-8, 2019 and pursuing sales of Company products and services.
Co-Diagnostics invites all interested parties to booth #2982, located in Hall C. The Company will use the opportunity to generate increased interest and sales in its infectious disease diagnostics vertical, and to introduce and promote the applications of their CoPrimer™ technology for next-generation sequencing, liquid biopsy cancer detection, and SNP differentiation to industry leaders.
The AACC is the world’s largest laboratory medicine expo, providing opportunities for over 19,000 scientists, manufacturers and distributors in the IVD and biotech communities to connect and engage in direct sales of their product offerings. Expo statistics from participants surveys indicate that 60% of attendees consider their primary business interest in attending the AACC to evaluate and acquire lab products or services, 31% of attendees intend to make a purchase within 1 year, and 58% plan to do so within 2 years following interactions with AACC exhibitors.
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets a new, state-of-the-art diagnostics technology. The Company’s technology is utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests to locate genetic markers for use in industries other than infectious disease and license the use of those tests to specific customers.
This press release contains forward-looking statements. Forward-looking statements can be identified by words such as "believes," "expects," "estimates," "intends," "may," "plans," "will" and similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. Forward-looking statements in this release include statements regarding the (i) use of funding proceeds, (ii) expansion of product distribution, (iii) acceleration of initiatives in liquid biopsy and SNP detection, (iv) use of the Company’s liquid biopsy tests by laboratories, (v) capital resources and runway needed to advance the Company’s products and markets, (vi) increased sales in the near-term, (vii) flexibility in managing the Company’s balance sheet, (viii) anticipation of business expansion, and (ix) benefits in research and worldwide accessibility of the CoPrimer technology and its cost-saving and scientific advantages. Forward-looking statements are subject to inherent uncertainties, risks and changes in circumstances. Actual results may differ materially from those contemplated or anticipated by such forward-looking statements. Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.
Company Sales Contact:
Head of International Sales
+1 801-438-1036 #2